1Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neu- tropenia [ J ]. J Clin Oncol, 1996,14 (2) :636-643.
4Chindaprasirt J, Wanitpongpun C, Limpawattana P, et al. Mortality, length of stay, and cost associated with hospital- ized adult cancer patients with febrile neutropenia [ J ]. Asi- an Pac J Cancer Prey,2013,14(2) :1115-1119.
5Choi SM, Park SH, Lee DG, et al. Current antimicrobial usage for the management of neutropenic fever in Korea:a nation- wide survey [ J ]. J Korean Med Sci,2008,23 (6) :941-947.
6Viscoli C, Bruzzi P, Castagnola E, et al. Antimicrobial Ther- apy Cooperative Group (IATCG) of the European Organi- zation for Research and Treatment of Cancer (EORTC) [ J ]. Eur J Cancer, 1994,30A(4) :430-437.
8Talcott JA, Finberg R, Mayer R J, et al. The medical course of cancer patients with fever and neutropenia: Clinical identifi- cation of a low-risk subgroup at presentation [ J ]. Arch In- tern Med, 1988,148 ( 12 ) :2561-2568.
9Klastersky J,Paesmans M, Rubenstein EB,et al. The Muhi- national Association for Supportive Care in Cancer risk in- dex:A multinational scoring system for identifying low-risk febrile neutropenic cancer patients [ J ]. J Clin Oncol, 2000,18 (16) :3038-3051.
10Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer :2010 Update by the infectious diseases society of america [ J ]. Clin Infect Dis ,2011,52 : e56-e93.
3Segal BH,Baden LR,Brown AE,et al.NCCN Clinical Practice Guidelines in Oncology.Prevention and Treatment of Cancer-related Infections.NCCN,V.2,2009.
4Freifeld A,Boeckh M,Bow EJ,et al.Clinical Practice Guideline for the Use of Antimicrobial agents in Neutropenic Patients with Cancer.Infectious Diseases Society of America(IDSA),2007.
5de Naurois J, Novitzky-Basso I, Gill M J, et al. Management of fe- brile neutropenia: ESMO Clinical Practice Guidelines[ J l. Ann Oncol,2010,21 Suppl 5 : v252-v256. DOI: 10. 1093/annonc/ mdq196.
6Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and an- ti-inflammatory properties of the cytokine interleukin-6 [ J ]. Bio- chim Biophys Acta, 2011,1813(5) :878-888. DOI: 10. 1016/j. bbamcr. 2011.01. 034.
7Andaluz-Ojeda D, Bobillo F, Iglesias V, et al. A combined score of pro- and anti-inflammatory interleukins improves mortality pre- diction in severe sepsis [ J . Cytokine, 2012,57 ( 3 ) : 332-336. DOI: 10. 1016/j. cyto. 2011.12. 002.
8Adib-Conquy M, Cavaillon JM. Host inflammatory and anti-in- flammatory response during sepsis [ J ]. Pathol Biol ( Paris ) , 2012,60(5 ) :306-313. DOI : 10. 1016/j. patbio. 2012.03.011.
9Steinmetz HT, Herbertz A, Bertram M, et al. Increase in interleu- kin-6 serum level preceding fever in granulocytopenia and correla- tion with death from sepsis [ J ]. J Infect Dis, 1995,171 (1) :225- 228.
10Mege JL, Meghari S, Honstettre A, et al. The two faces of inter- leukin 10 in human infectious diseases [ J]. Lancet Infect Dis, 2006,6(9) :557-569. DOI: 10. 1016/S1473-3099(06)70577-1.
